ǰÑÔ
´¹ÌåÁö(pituitary tumor)ÊÇÒ»ÖÖ³£¼ûµÄÂÄÚÖ×Áö£¬Ô¼Õ¼ÂÄÚÖ×ÁöµÄ10£¥~15£¥¡£´¹Ìå¿É·Ö³É´¹ÌåǰҶ£¨ÏÙ´¹Ì壩ºÍ´¹ÌåºóÒ¶£¨Éñ¾´¹Ì壩Á½´ó²¿·Ö¡£´¹ÌåǰҶϸ°ûÉøÍ¸ÃÚÈéËØ(prolactin,PRL)¡¢´ÙÉöÉÏÏÙÆ¤Öʼ¤ËØ(adrenocorticotropic hormone,ACTH)¡¢ÂÑÅݴ̼¤ËØ(follicle stimulating hormone,FSH)ºÍÐþɫϸ°û´Ì¼¤ËØ(melanocyte stimulating hormone,MSH)µÈ¡£Éñ¾´¹Ìå×Ô¼º²»ÖÆÔì¼¤ËØ£¬¶øÊÇÆðÒ»¸ö¿ÍÕ»µÄ×÷Óá£ÏÂÇðÄÔµÄÊÓÉϺ˺ÍÊÒÅÔºËÌìÉúµÄ¿¹ÀûÄò¼¤Ëغʹ߲úËØ£¬Í¨¹ýÏÂÇðÄÔÓë´¹ÌåÖ®¼äµÄÉñ¾ÏËά±»Ë͵½Éñ¾´¹ÌåÖü´æÆðÀ´£¬µ±ÉíÌåÐèҪʱ¾ÍÊͷŵ½ÑªÒºÖС£
´¹ÌåÁöÒÔǰҶµÄÏÙÁöÕ¼´ó´ó¶¼£¬À´×ÔºóÒ¶ÕßÉÙ¼û¡£´¹ÌåÁöµÄÖ¢×´ÌåÕ÷Ö÷ÒªÊÇÓÉÓÚÖ×ÁöµÄ¾Ö²¿Õ¥È¡£¬»ò¼¤ËØÉøÍ¸¹ý¶à£¬»òÒòÖÎÁÆÒýÆðµÄ¼¤ËØÉøÍ¸È±·¦¶øÌåÏÖ³öһϵÁеÄÁÙ´²ÌåÏÖ¡£Ö×Áöեȡ´¹ÌåÖÜΧ×éÖ¯ÌåÏÖΪһÁ¬ÐÔÍ·Í´£¬ÊÓ½»Ö¯¼°ÊÓÉñ¾ÊøÕ¥È¡Ö¢£¬·ºÆðÊÓÁ¦¼õÍË¡¢ÊÓҰȱËðºÍÑ۵׸ıäµÈ¡£¼¤ËØÉøÍ¸Òì³£ÌåÏÖΪ¹¦Ð§ÐÔÖ×Áöϸ°ûÉøÍ¸¹ý¶à¼¤ËØ£¬ÈçÉú³¤¼¤Ëعý¶àÒýÆðÖ«¶Ë·Ê´óÖ¢£¬»òÎÞ¹¦Ð§ÐÔÖ×ÁöÔö´ó£¬ÆÆËðÕý³£´¹Ìå×é֯ʱÒýÆð¼¤ËØÉøÍ¸¹ýÉÙ£¬Èç´ÙÐÔÏÙ¼¤ËØÉøÍ¸ïÔ̶ø±Õ¾¡¢²»Óý»òÑôήµÈ¡£
´¹ÌåÁö¶¯ÎïÄ£×Ó¿É·ÖΪÓÕ·¢ÐÔ´¹ÌåÁöÄ£×Ó¡¢×Ô¾õÐÔ´¹ÌåÁöÄ£×Ó¡¢ÒÆÖ²ÐÔ´¹ÌåÁöÄ£×ÓÒÔ¼°»ùÒòÐÞÊδ¹ÌåÁöÄ£×ÓËÄÀà¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯Î´óÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
¶¯Îï×Ô¾õÐÔ´¹ÌåÁö(spontaneous pituitary tumor)µÄ±¬·¢ÂÊÓ붯ÎïµÄƷϵ¡¢ÐÔ±ð¡¢ÄêËêÓйء£ÈçCD1СÊó´¹ÌåÁöµÄ±¬·¢ÂÊΪ1.1%,F344 ´óÊó´¹ÌåÁöµÄ±¬·¢ÂÊΪ20.5£¥,Sprague DawleyÐÛÐÔ´óÊóΪ47£¥¡¢´ÆÐÔΪ62£¥£»Wistar-FurthÐÛÐÔ´óÊó72~116ÖÜΪ6£¥¡¢´ÆÐÔ64~135Öܸߴï69£¥¡£´¹ÌåÁö±¬·¢ÂÊËæÄêËêµÄÔö´ó¶øÔöÌí£¬50ÖÜÒÔÏ´óÊó×Ô¾õÐÔ´¹ÌåÁöµÄ±¬·¢Âʼ«µÍ¡£
¡¾ÔìÄ£ÒªÁì¡¿£º
ÌôÑ¡ÍíÄê×Ô¾õÐÔ´¹ÌåÁö±¬·¢ÂʸߵĴóÊóƷϵÈçWistar-Furth´óÊó¾ÙÐÐÑо¿¡£
¡¾Ä£×ÓÌØµã¡¿£º
Wistar-Furth´óÊó×Ô¾õÐÔ´¹ÌåÁöÓëÈËÓÐÐí¶àÏàËÆÖ®´¦£º´ÆÐÔ±¬·¢Âʽϸߣ»Ö»ÉøÍ¸PRL²¢ÇÒºÍÖ×ÁöµÄ¾ÞϸÓйأ»×éÖ¯ÐÎÌ¬Ñ§ÌØµã¡¢ÄÚÉøÍ¸ÒÔ¼°Ò©ÎïÃô¸ÐÐÔ·½ÃæÒÔ¼°Ö×ÁöµÄÁ¼ÐÔÌØÕ÷ÓëÈËÀàPRLÁöÏàËÆ£»¾ßÓпÉÒÆÖ²ÐÔ£¬ÔÚ´¹ÌåÁö£¨Ö÷ÒªÊÇPRLÁö£©µÄ»ù´¡ºÍÁÙ´²Ñо¿ÉÏÓкܴóµÄ¼ÛÖµ¡£
¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º
´ËÄ£×ÓÓ¦ÓÃÓÚ´¹ÌåÁöµÄ·¢²¡»úÖÆ¡¢×éÖ¯²¡ÀíѧÑо¿£»Òà¿ÉÓÃ×Ô¾õÐÔ´¹ÌåÁö¾ÙÐÐÒÆÖ²ÁöÑо¿¡£¿É½«×Ô¾õÐÔ´¹ÌåÁöÔÚÌåÍâ¾ÙÐÐ×÷ÓýÑо¿£¬ÔÙÒÆÖ²½ÓÖÖµ½¶¯ÎïÉíÉϾÙÐÐÑо¿¡£×Ô¾õÐÔ´¹ÌåÁöÄ£×Ó²»¿É»ñµÃÆÕ±éµÄÓ¦ÓÃÆäÔµ¹ÊÔÓÉÊÇ£ºÐèÒªËÇÑøÊ±¼ä³¤£¬¾ÓÉɸѡ²Å»ª»ñµÃºÏÊʵ͝ÎïÄ£×Ó£»ËÇÑø±¾Ç®½Ï´ó£»´¹ÌåÁöÌå»ýС¡¢Î»ÖÃÉ²»Ò×ÊÓ²ìºÍÕÉÁ¿£»Ö×Áö½Ï´óʱեȡÊÓÇðϲ¿µ¼ÖÂͻȻéæÃü¡£
²Î¿¼ÎÄÏ×£º
1.ÕÅÃÍ£¬ÕÅÇïÉú£¬ÁÖºãÖÝ£¬µÈ. ÒÒÏ©´Æ·ÓÓÕµ¼µÄ´óÊó´¹ÌåÁöÄ£×ӵĽ¨É裮Öйú²¡ÀíÐÄÀíÔÓÖ¾£¬2012, 28 (8): 1532-1536
2.Helseth A, Siegal GP, Haug E, et al Transgenic mice that develop pituitary tumors. A model for Cushing's disease£®Am J Pathol, 1992, 140 (5):1071-1080
3.Cristina C, Garc í a-Tornad ú I, D í az-Torga G, et al.Doparninergic 02 receptor knockout mouse: an animal model of prolactinoma. Front Horm Res, 2006, 35: 50-63
4.Ishii J, Kawakami Y. Recent progress in experimental pituitary tumors in various animals. Nihon Rinsho, 1993, 51 (10):2580-2584
5.Fedele M, Battista S, Kenyon L, et al. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene,2002,21 (20):3190-3198
6.Pernasetti F, Spacly TJ, Hall SB,et al. Pituitary turnorigenesi targeted by the ovine follicle-stimulating hormone betasubunit gene regulatory region in transgenic mice. Mol Cell Endocrinol, 2003,203 (1-2): 169-183